Your browser doesn't support javascript.
loading
An AsCas12f-based compact genome-editing tool derived by deep mutational scanning and structural analysis.
Hino, Tomohiro; Omura, Satoshi N; Nakagawa, Ryoya; Togashi, Tomoki; Takeda, Satoru N; Hiramoto, Takafumi; Tasaka, Satoshi; Hirano, Hisato; Tokuyama, Takeshi; Uosaki, Hideki; Ishiguro, Soh; Kagieva, Madina; Yamano, Hiroyuki; Ozaki, Yuki; Motooka, Daisuke; Mori, Hideto; Kirita, Yuhei; Kise, Yoshiaki; Itoh, Yuzuru; Matoba, Satoaki; Aburatani, Hiroyuki; Yachie, Nozomu; Karvelis, Tautvydas; Siksnys, Virginijus; Ohmori, Tsukasa; Hoshino, Atsushi; Nureki, Osamu.
  • Hino T; Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
  • Omura SN; Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.
  • Nakagawa R; Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.
  • Togashi T; Department of Biochemistry, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan; Department of Clinical Laboratory Science, Division of Health Sciences, Graduate School of Medical Science, Kanazawa University, Ishikawa 920-0942, Japan.
  • Takeda SN; Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.
  • Hiramoto T; Department of Biochemistry, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan.
  • Tasaka S; Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
  • Hirano H; Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.
  • Tokuyama T; Division of Regenerative Medicine, Center for Molecular Medicine, Jichi Medical University, Tochigi 329-0498, Japan.
  • Uosaki H; Division of Regenerative Medicine, Center for Molecular Medicine, Jichi Medical University, Tochigi 329-0498, Japan.
  • Ishiguro S; School of Biomedical Engineering, Faculty of Applied Science and Faculty of Medicine, The University of British Columbia, Vancouver, BC V6S 0L4, Canada.
  • Kagieva M; School of Biomedical Engineering, Faculty of Applied Science and Faculty of Medicine, The University of British Columbia, Vancouver, BC V6S 0L4, Canada.
  • Yamano H; Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
  • Ozaki Y; Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
  • Motooka D; Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Osaka 565-0871, Japan.
  • Mori H; Institute for Advanced Biosciences, Keio University, Yamagata 997-0035, Japan; Graduate School of Media and Governance, Keio University, Fujisawa, Kanagawa 252-0882, Japan; Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), Osaka University, Suita, Osaka, 565-0871, Japan.
  • Kirita Y; Department of Nephrology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
  • Kise Y; Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan; Curreio, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
  • Itoh Y; Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.
  • Matoba S; Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
  • Aburatani H; Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan.
  • Yachie N; School of Biomedical Engineering, Faculty of Applied Science and Faculty of Medicine, The University of British Columbia, Vancouver, BC V6S 0L4, Canada; Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), Osaka University, Suita, Osaka, 565-0871, Japan; Synthetic Biology Division, R
  • Karvelis T; Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Siksnys V; Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Ohmori T; Department of Biochemistry, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan; Center for Gene Therapy Research, Jichi Medical University, Tochigi 329-0498, Japan. Electronic address: tohmori@jichi.ac.jp.
  • Hoshino A; Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. Electronic address: a-hoshi@koto.kpu-m.ac.jp.
  • Nureki O; Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan. Electronic address: nureki@bs.s.u-tokyo.ac.jp.
Cell ; 186(22): 4920-4935.e23, 2023 10 26.
Article en En | MEDLINE | ID: mdl-37776859
ABSTRACT
SpCas9 and AsCas12a are widely utilized as genome-editing tools in human cells. However, their relatively large size poses a limitation for delivery by cargo-size-limited adeno-associated virus (AAV) vectors. The type V-F Cas12f from Acidibacillus sulfuroxidans is exceptionally compact (422 amino acids) and has been harnessed as a compact genome-editing tool. Here, we developed an approach, combining deep mutational scanning and structure-informed design, to successfully generate two AsCas12f activity-enhanced (enAsCas12f) variants. Remarkably, the enAsCas12f variants exhibited genome-editing activities in human cells comparable with those of SpCas9 and AsCas12a. The cryoelectron microscopy (cryo-EM) structures revealed that the mutations stabilize the dimer formation and reinforce interactions with nucleic acids to enhance their DNA cleavage activities. Moreover, enAsCas12f packaged with partner genes in an all-in-one AAV vector exhibited efficient knock-in/knock-out activities and transcriptional activation in mice. Taken together, enAsCas12f variants could offer a minimal genome-editing platform for in vivo gene therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sistemas CRISPR-Cas / Edición Génica Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sistemas CRISPR-Cas / Edición Génica Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article